DIFFERENTIAL CHARACTERISTICS OF THE MEANS OF PREVENTION OF PRIMARY PLACENTAL DYSFUNCTION IN WOMEN WITH INFLAMMATORY DISEASES OF THE FEMALE GENITAL ORGANS
DOI:
https://doi.org/10.32782/2226-2008-2025-1-8Keywords:
placental dysfunction, prevention, inflammatory diseases of the female genital organsAbstract
The prevention and treatment of placental dysfunction in pregnant women against the background of inflammatory diseases of the female genital organs should begin with the elimination of the causes that provoke a violation of the placenta’s function and structure, and the treatment measures carried out for pregnant women with placental dysfunction should be timely, pathogenetically justified, and comprehensive. Materials and methods. To evaluate the effectiveness of PD prevention, the main group of women was divided into 2 subgroups: 1st subgroup – IA women who received PD prevention and specific treatment of inflammatory diseases of the female genital organs in the first trimester of pregnancy; 2nd subgroup – IB women who received prevention of PD and specific treatment of inflammatory diseases of the female genital organs in the second trimester of pregnancy. Studies of uteroplacental blood circulation were conducted using the ultrasonic diagnostic device “SonoAce 8000 Life”. Results. According to the ultrasound results of the women of the main group, it was found that the thickness of the placenta at the end of the III trimester of pregnancy in the women of the main (IB) group had significant differences from the women of the IA subgroup and the indicators of the control group. Detection of ultrasound indicators of intrauterine infection of the fetus, namely, ascites, hepatosplenomegaly, SZRP, increase in the size of the abdomen, and pyelectasis, confirms intoxication effects of the fetus in women against the background of TORCH – infection.
References
Bulavenko OV, Muntyan ÎÀ, Konkov DH, Furman OV. Ultrasound characteristics of blood circulation in uterine vessels in the I trimester of pregnancy in women with the history of recurrent miscarriage. Reports of Vinnytsia National Medical University. 2019; 22(1):72–76. doi: 10.31393/reports-vnmedical-2019-22(1)-14.
Herman LV. Optimization of diagnosis and treatment of placental dysfunction in pregnant women with miscarriage : abstract of thesis. Kyiv. 2019. 27 p.
Klymnyuk SI, Mуkhailyshyn GI, Malanchuk LM. Microbiological features of bacterial vaginosis in women of different age categories and ways of their microbiological correction. Achievements of Clinical and Experimental Medicine. 2021; 3:21–31. doi: 10.11603/1811-2471.2019.v.i3.10258.
Podolskyi VlV, Podolskyi VV. Modern options of outpatient treatment of chronic inflammatory diseases in fertile aged women caused. Health of Woman. 2020; 5:132–136. doi: 10.15574/HW.2019.121.132.
Khits AR. Bacterial vaginosis: current state of the problem and review of the latest international guidelines. Ukrainian Medical Journal. 2021; 1:1–3. Available from: https://api.umj.com.ua/wp/wp-content/uploads/2021/02/Vaginos.pdf.
Dall’Asta A, Minopoli M, Ghi, T, Frusca T. Monitoring, Delivery and Outcome in Early Onset Fetal Growth Restriction. Reprod Med. 2021; 2(2):85–94. doi: 10.3390/reprodmed2020009.
Ferrazzi E, Stampalija T, Monasta L, Di Martino D, Vonck S, Gyselaers W. Maternal hemodynamics: a method to classify hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2018; 218(1):124.e1–124.e11. doi: 10.1016/j.ajog.2019.10.226.
Heazell AE, Hayes DJ, Whitworth M, Takwoingi Y, Bayliss SE, Davenport C. Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants. Cochrane Database Syst Rev. 2019; 5(5):CD012245. doi: 10.1002/14651858.cd012245.pub2.
Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS. 2019 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2019; 29(13):1258–1272. doi: 10.1177/0956462418785451.
Skeith L, Rodger M. Anticoagulants to prevent recurrent placenta-mediated pregnancy complications: is it time to put the needles away? Thromb Res. 2019; 151(Suppl 1):S38–S42. doi: 10.1016/s0049-3848(17)30065-8.
Heazell AE, Hayes DJ, Whitworth M, Takwoingi Y, Bayliss SE, Davenport C. Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants. Cochrane Database Syst Rev. 2019; 5(5):CD012245. doi: 10.1002/14651858.cd012245.pub2.
Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018; 29(13):1258–1272. doi: 10.1177/0956462418785451.
Skeith L, Rodger M. Anticoagulants to prevent recurrent placenta-mediated pregnancy complications: is it time to put the needles away? Thromb Res. 2017; 151(Suppl 1):S38–S42. doi: 10.1016/s0049-3848(17)30065-8.
